Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

1.9K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.9K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

2.9K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.9K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

4.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

766
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
766
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

443
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
443

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coronary plaque burden assessed by coronary CT angiography in individuals with type 1 diabetes and healthy controls.

The international journal of cardiovascular imaging·2026
Same author

Corrigendum: National Early Warning Score for Predicting Clinical Outcome of Acute Pulmonary Embolism in Intermediate-High Risk Patients.

TH open : companion journal to thrombosis and haemostasis·2025
Same author

National Early Warning Score for Predicting Clinical Outcome of Acute Pulmonary Embolism in Intermediate-High Risk Patients.

TH open : companion journal to thrombosis and haemostasis·2025
Same author

A systematic literature review and meta-analysis of real-world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes.

Diabetes, obesity & metabolism·2025
Same author

Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.

Diabetes, obesity & metabolism·2025
Same author

Automated Insulin Delivery Versus Standard of Care in the Management of People Living with Type 1 Diabetes and HbA1c <8%: A Cost-Utility Analysis in The Netherlands.

Diabetes technology & therapeutics·2025

Related Experiment Video

Updated: Dec 12, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.1K

National diabetes registries: do they make a difference?

Jessica C G Bak1, Erik H Serné1, Mark H H Kramer1

  • 1Department of Vascular Medicine, Amsterdam UMC, Location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Acta Diabetologica
|August 10, 2020
PubMed
Summary
This summary is machine-generated.

National diabetes registries offer insights into patient care and outcomes. A standardized global outcome set could improve data comparison and resource allocation for diabetes mellitus management.

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.2K
Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature
05:54

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

557

Related Experiment Videos

Last Updated: Dec 12, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.1K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.2K
Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature
05:54

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

557

Area of Science:

  • Endocrinology and Metabolism
  • Public Health
  • Health Services Research

Background:

  • The global diabetes mellitus epidemic significantly impacts national healthcare systems.
  • Measuring diabetes outcomes is crucial for identifying care improvements and efficiency gains.
  • National registries hold potential for comprehensive diabetes outcome assessment.

Purpose of the Study:

  • To provide a global overview of national diabetes registries.
  • To quantify the data captured by these registries.
  • To assess their influence on diabetes care and healthcare policy.

Main Methods:

  • Systematic literature search of MEDLINE up to March 31, 2020.
  • Inclusion of national disease-specific diabetes registries.
  • Comparison of registry characteristics and clinical variables against the ICHOM standard set of outcomes.

Main Results:

  • Identified 12 national clinical diabetes registries covering 7,181,356 patients.
  • Key variables like weight, HbA1c, lipid profile, and insulin treatment were commonly recorded.
  • Registries generally aligned with ICHOM standards and aided in monitoring and improving diabetes care quality.

Conclusions:

  • National diabetes registries provide valuable insights into diagnostics, complications, and treatment.
  • Their influence on national healthcare policy was variable and less evident.
  • A standardized global outcome set could enhance data concordance, comparison, and targeted resource allocation.